Teva Pharmaceutical Industries (TEVA) Cash from Operations (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Cash from Operations came in at 411000000.0 in Q2 2026, up 81.06% YoY from 227000000.0 in Q2 2025, and up 1127.5% on a QoQ basis from 40000000.0 in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Cash from Operations (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Cash from Operations data on file, last reported at 411000000.0 in Q2 2026.
- Quarterly Cash from Operations rose 81.06% year-over-year to 411000000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 1898000000.0 (up 36.55% YoY) and the FY2025 annual result came in at 1649000000.0, up 32.24% from the prior year.
- Cash from Operations grew to 411000000.0 in Q2 2026, from 40000000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1184000000.0 in Q4 2023 to a low of 145000000.0 in Q1 2023.
- A 5-year average of 345833333.33 and a median of 275500000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations tumbled 195.92% — and 2024, when it soared 13760.0%.
- Tracing TEVA's Cash from Operations over 5 years: stood at 973000000.0 in 2022, then gained by 21.69% to 1184000000.0 in 2023, then slumped by 51.44% to 575000000.0 in 2024, then soared by 101.39% to 1158000000.0 in 2025, then slumped by 64.51% to 411000000.0 in 2026.
- The last three Cash from Operations figures came in at 411000000.0 (Q2 2026), 40000000.0 (Q1 2026), and 1158000000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 411.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 655.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 800.69 Mn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 313.60 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 381.80 Mn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 136.40 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 277.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | 145.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 411.00 Mn |
| Jun 30, 2026 | 411.00 Mn |
| Mar 31, 2026 | -40.00 Mn |
| Mar 31, 2026 | -40.00 Mn |
| Dec 31, 2025 | 1.16 Bn |
| Dec 31, 2025 | 1.16 Bn |
| Sep 30, 2025 | 369.00 Mn |
| Sep 30, 2025 | 369.00 Mn |
| Jun 30, 2025 | 227.00 Mn |
| Jun 30, 2025 | 227.00 Mn |
| Mar 31, 2025 | -105.00 Mn |
| Mar 31, 2025 | -105.00 Mn |
| Dec 31, 2024 | 575.00 Mn |
| Dec 31, 2024 | 575.00 Mn |
| Sep 30, 2024 | 693.00 Mn |
| Sep 30, 2024 | 693.00 Mn |
| Jun 30, 2024 | 103.00 Mn |
| Jun 30, 2024 | 103.00 Mn |
| Mar 31, 2024 | -124.00 Mn |
| Mar 31, 2024 | -124.00 Mn |